STLNW
Oncology Institute, Inc. Warrant 2021-15.11.26 on Oncology Inst
NASDAQ · Healthcare · Medical - Care Facilities · US
$0.02
+14.43%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +40.4%
- EBITDA
- +157.3%
- EPS
- +91.9%
Three-year CAGR
- Revenue
- +25.8%
- EBITDA
- +21.0%
- EBIT
- +40.0%
- Net income
- +6.3%
- EPS
- +23.9%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026